Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2016 - 2025)

Fennec Pharmaceuticals' Income from Continuing Operations history spans 15 years, with the latest figure at 2133000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 242.11% year-over-year to 2133000.0, compared with a TTM value of 2809000.0 through Dec 2025, down 1651.93%, and an annual FY2025 reading of 9741000.0, down 180.8% over the prior year.
  • Income from Continuing Operations for Q4 2025 was 2133000.0 at Fennec Pharmaceuticals, up from 623000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 12906000.0 in Q1 2024, with the low at 7994000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 2891368.42, with a median of 3917000.0 recorded in 2021.
  • Biggest YoY gain for Income from Continuing Operations was 316.58% in 2024; the steepest drop was 222.47% in 2024.
  • Tracing FENC's Income from Continuing Operations over 5 years: stood at 4215000.0 in 2021, then crashed by 63.58% to 6895000.0 in 2022, then soared by 62.03% to 2618000.0 in 2023, then skyrocketed by 42.67% to 1501000.0 in 2024, then surged by 242.11% to 2133000.0 in 2025.
  • Per Business Quant, the three most recent readings for FENC's Income from Continuing Operations are 2133000.0 (Q4 2025), 623000.0 (Q3 2025), and 3155000.0 (Q2 2025).